February 16, 2024Open Access

Supplementary Figure S2 from Pim Kinase Inhibitors Increase Gilteritinib Cytotoxicity in FLT3-ITD Acute Myeloid Leukemia Through GSK-3β Activation and c-Myc and Mcl-1 Proteasomal Degradation

View Full Paper

Ask AI

Bookmark

Abstract

Concurrent Pim and FLT3 inhibitor treatment inhibits AKT, but GSK-3β activation, c-Myc and Mcl-1 downregulation and apoptosis induction are independent of AKT inhibition as well as ERK inhibition.

Discussion

No takes yet. Share an insight, caveat, or question.

Cite This Study

Lee et al. (2024) studied this question.

synapsesocial.com/papers/68e78e41b6db643587700455 https://doi.org/10.1158/2767-9764.25233485

View Full Paper

Ask AI

Bookmark

Abstract

Concurrent Pim and FLT3 inhibitor treatment inhibits AKT, but GSK-3β activation, c-Myc and Mcl-1 downregulation and apoptosis induction are independent of AKT inhibition as well as ERK inhibition.

Supplementary Figure S2 from Pim Kinase Inhibitors Increase Gilteritinib Cytotoxicity in FLT3-ITD Acute Myeloid Leukemia Through GSK-3β Activation and c-Myc and Mcl-1 Proteasomal Degradation

Abstract

Discussion

Cite This Study

Supplementary Figure S2 from Pim Kinase Inhibitors Increase Gilteritinib Cytotoxicity in FLT3-ITD Acute Myeloid Leukemia Through GSK-3β Activation and c-Myc and Mcl-1 Proteasomal Degradation

Abstract

Discussion

Cite This Study

Keep reading

Keep reading